AI assistant
BIO-TECHNE Corp — Director's Dealing 2023
Sep 1, 2023
30718_dirs_2023-09-01_502c5208-dcfa-4404-ad15-88ab539ac004.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2023-08-30
Reporting Person: Nusse Roeland (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-30 | Common Stock | M | 16000 | $21.85 | Acquired | 44811 | Direct |
| 2023-08-30 | Common Stock | M | 16000 | $22.95 | Acquired | 60811 | Direct |
| 2023-08-30 | Common Stock | S | 8939 | $80.3176 | Disposed | 51872 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-30 | Stock Options (Right to Buy) | $21.85 | M | 16000 | Disposed | 2023-10-30 | Common Stock (16000) | Direct |
| 2023-08-30 | Stock Options (Right to Buy) | $22.95 | M | 16000 | Disposed | 2024-10-30 | Common Stock (16000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $21.84 | 2025-10-28 | Common Stock (17040) | 17040 | Direct |
| Stock Options (Right to Buy) | $25.30 | 2026-10-27 | Common Stock (15940) | 15940 | Direct |
| Stock Options (Right to Buy) | $31.26 | 2027-10-26 | Common Stock (12500) | 12500 | Direct |
| Stock Options (Right to Buy) | $44.96 | 2028-10-25 | Commo Stock (7592) | 7592 | Direct |
| Stock Options (Right to Buy) | $50.41 | 2029-10-24 | Common Stock (8044) | 8044 | Direct |
| Stock Options (Right to Buy) | $63.92 | 2030-10-29 | Common Stock (6028) | 6028 | Direct |
| Stock Options (Right to Buy) | $128.81 | 2031-10-28 | Common Stock (2532) | 2532 | Direct |
| Stock Options (Right to Buy) | $73.94 | 2032-10-27 | Common Stock (3460) | 3460 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.09 to $80.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders.